Grail, Inc. (NASDAQ:GRAL - Get Free Report) CFO Aaron Freidin sold 30,452 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the completion of the sale, the chief financial officer now owns 268,277 shares of the company's stock, valued at approximately $3,761,243.54. The trade was a 10.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Grail Trading Up 5.6 %
Shares of NASDAQ GRAL opened at $14.79 on Wednesday. Grail, Inc. has a 12-month low of $12.33 and a 12-month high of $23.36. The firm has a 50-day simple moving average of $13.84.
Analyst Ratings Changes
Several analysts recently weighed in on the stock. Guggenheim assumed coverage on shares of Grail in a report on Thursday, October 17th. They issued a "neutral" rating for the company. Wolfe Research started coverage on shares of Grail in a research note on Friday, November 15th. They set a "peer perform" rating on the stock.
Read Our Latest Report on GRAL
About Grail
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
